nocodazole has been researched along with Melanoma in 7 studies
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nuclear iASPP is enriched in melanoma metastasis and associates with poor patient survival." | 1.39 | Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. ( Baer, C; Breyssens, H; Brown, NR; Caballero, OL; Cebon, J; Endicott, J; Goding, CR; Hu, Y; John, T; Jones, EY; Kessler, BM; Knapp, S; Lu, M; Lu, X; Middleton, MR; Ratnayaka, I; Salter, V; Siebold, C; Sullivan, A; Sviderskaya, EV; Zhong, S, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Mahboobi, S | 1 |
| Pongratz, H | 1 |
| Hufsky, H | 1 |
| Hockemeyer, J | 1 |
| Frieser, M | 1 |
| Lyssenko, A | 1 |
| Paper, DH | 1 |
| Bürgermeister, J | 1 |
| Böhmer, FD | 1 |
| Fiebig, HH | 1 |
| Burger, AM | 1 |
| Baasner, S | 1 |
| Beckers, T | 1 |
| Endo, Y | 1 |
| Saeki, K | 1 |
| Watanabe, M | 1 |
| Miyajima-Magara, N | 1 |
| Igarashi, M | 1 |
| Mochizuki, M | 1 |
| Nishimura, R | 1 |
| Sugano, S | 1 |
| Sasaki, N | 1 |
| Nakagawa, T | 1 |
| Lu, M | 1 |
| Breyssens, H | 1 |
| Salter, V | 1 |
| Zhong, S | 1 |
| Hu, Y | 1 |
| Baer, C | 1 |
| Ratnayaka, I | 1 |
| Sullivan, A | 1 |
| Brown, NR | 1 |
| Endicott, J | 1 |
| Knapp, S | 1 |
| Kessler, BM | 1 |
| Middleton, MR | 1 |
| Siebold, C | 1 |
| Jones, EY | 1 |
| Sviderskaya, EV | 1 |
| Cebon, J | 1 |
| John, T | 1 |
| Caballero, OL | 1 |
| Goding, CR | 1 |
| Lu, X | 1 |
| Spangler, B | 1 |
| Kappelmann, M | 1 |
| Schittek, B | 1 |
| Meierjohann, S | 1 |
| Vardimon, L | 1 |
| Bosserhoff, AK | 1 |
| Kuphal, S | 1 |
| Wang, Q | 1 |
| Moyret-Lalle, C | 1 |
| Couzon, F | 1 |
| Surbiguet-Clippe, C | 1 |
| Saurin, JC | 1 |
| Lorca, T | 1 |
| Navarro, C | 1 |
| Puisieux, A | 1 |
| Sjoberg, ER | 1 |
| Chammas, R | 1 |
| Ozawa, H | 1 |
| Kawashima, I | 1 |
| Khoo, KH | 1 |
| Morris, HR | 1 |
| Dell, A | 1 |
| Tai, T | 1 |
| Varki, A | 1 |
| Fink-Puches, R | 1 |
| Hofmann-Wellenhof, R | 1 |
| Smolle, J | 1 |
| Helige, C | 1 |
| Kerl, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Decitabine and Arsenic Trioxide(ATO) in the Treatment of Myelodysplasic Syndrome[NCT03377725] | Phase 3 | 0 participants (Actual) | Interventional | 2018-03-20 | Withdrawn (stopped due to No patient was involved.) | ||
| Decitabine,Cytarabine(Ara-C) and Arsenic Trioxide(ATO) in the Treatment of Acute Myeloid Leukemia With p53 Mutations[NCT03381781] | Phase 2 | 100 participants (Anticipated) | Interventional | 2018-03-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 other studies available for nocodazole and Melanoma
| Article | Year |
|---|---|
Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents.
Topics: Allantois; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biopolymers; Cattle; Chorion; Dr | 2001 |
Spindle assembly checkpoint competence in aneuploid canine malignant melanoma cell lines.
Topics: Aneuploidy; Animals; Cell Cycle Proteins; Cell Line, Tumor; Chromatids; Dog Diseases; Dogs; Histones | 2020 |
Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell | 2013 |
Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell | 2013 |
Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell | 2013 |
Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell | 2013 |
ETS-1/RhoC signaling regulates the transcription factor c-Jun in melanoma.
Topics: Cadherins; Cell Line, Tumor; Cytoskeleton; Humans; Melanoma; Nocodazole; Promoter Regions, Genetic; | 2012 |
Alterations of anaphase-promoting complex genes in human colon cancer cells.
Topics: Anaphase-Promoting Complex-Cyclosome; Antineoplastic Agents; Apc3 Subunit, Anaphase-Promoting Comple | 2003 |
Expression of de-N-acetyl-gangliosides in human melanoma cells is induced by genistein or nocodazole.
Topics: Antibodies, Monoclonal; Benzoquinones; Cell Line; Chromatography, High Pressure Liquid; Chromatograp | 1995 |
Cytoplasmic microtubules in two different mouse melanoma cell lines: a qualitative and quantitative analysis using confocal laser scanning microscopy and computer-assisted image analysis.
Topics: Animals; Female; Fluorescent Antibody Technique, Indirect; Image Processing, Computer-Assisted; Mela | 1997 |